Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Japan / NCT05913700
Active, not recruiting Observational

Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study)

NCT05913700 · tracked via the Priya Life Science Japan tracker
Sponsor
Institute for Clinical Effectiveness, Japan
Phase
Observational
Started
2023-07-01
Last updated
2025-07-20

Condition(s) studied

Respiratory Syncytial Virus (RSV)Respiratory Viral InfectionAcute Disease

Study summary

Study design is multicenter prospective registry study. Participants are consecutive (non-selected, a sequential registration) patients admitted from emergency rooms of participating hospitals who meet the eligibility criteria.

The primary objectives are to estimate the prevalence of and risk factors for RS and other respiratory virus infection and their effect on hospital course in patients with any respiratory symptom who admit from emergency room using a multicenter prospective registry study. The primary target virus is RS virus and the secondary target viruses are respiratory virus and other microorganisms measured by FilmArray 2.1.

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Aged 50 years or older * Admission from emergency room * Having at least one of following respiratory symptoms/signs for at least 24 hours and the onset date of first symptom/sign less than 7 days before admission, which meet the acute respiratory infection (ARI) case definition described below: nasal congestion, rhinorrhea, sore throat, cough, sputum, dyspnea, wheeze, crackles or rhonchi, tachypnea (\>=20 per minute), decreased saturation of oxygen (\< 95%), admission with oxygen supplementation Exclusion Criteria: * Scheduled admission * Admission for trauma care * With nasopharyngeal cavity diseases or deformity which block the nasopharyngeal sampling * Admission for end of life * Decline to participate the study by either informed consent or opt-out method

Primary outcome measure(s)

  • RS virus infection — On admission
    Presence of RS virus infection measured by FilmArray 2.1

Trial sites (3)

FacilityCityRegionStatus
Rakuwakai Otowa Hospital Kyoto Kyoto
Nara City Hospital Nara Nara
Shimane Prefectural Central Hospital Izumo Shimane

Other trials for the same condition

A Phase II Clinical Study to Evaluate the Efficacy and Safety of YKYY018 for Inhalation Solution Starting soon
Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05913700 on ClinicalTrials.gov ↗ ← All trials in Japan